GeneNews

The companies have signed a deal under which each will make its tests available to the other's customer base.

The company had to halt and later restart billing for its cancer risk assessment tests as it transitioned to a new billing process.

The company attributed the revenue decline to ongoing changes in how it bills for its diagnostics.

The company attributed the decline in revenues to changes it is making in the billing process for its diagnostics.

GeneNews said that it has decided to make an initial draw down of $500,000 to help "fuel the company's momentum while minimizing dilution."

The decline reflects a drop off in sales of its ColonSentry colorectal cancer blood test and other diagnostics.

GeneNews has signed a binding agreement with multinational private equity firm Milost Global for up to $10 million in equity and debt financing.

The company signed a US partnership agreement for its portfolio of early cancer detection tests with lab testing services provider Any Lab Test Now.

The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.